A Combinatorial Strategy for Targeting <i>BRAF</i> V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib) - Concepedia

Concepedia

Publication | Open Access

A Combinatorial Strategy for Targeting <i>BRAF</i> V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)

DOI Full Paper Access

23

Citations

36

References

2020

Year

Chandrayee Ghosh, Suresh Kumar, Yevgeniya Kushchayeva, Kelli Gaskins, Myriem Boufraqech, Darmood Wei, Sudheer Kumar Gara, Lisa Zhang, Yaqin Zhang, Min Shen,

Clinical Cancer Research

Abstract

Combination treatment with ponatinib and PLX4720 exhibited significant synergistic anticancer activity in preclinical models of <i>BRAF</i> <sup>V600E</sup> thyroid cancer, in addition to overcoming PLX4720 resistance. Our results suggest this combination should be tested in clinical trials.

References

	Year	Citations

Page 1